Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

SRPT Sarepta Therapeutics Inc New

108,30

-1,16 (-1,06%)

15 Feb 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

Click Here for more Sarepta Therapeutics Charts.

News Sarepta Therapeutics Inc New

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
Freitag 14 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 14 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 14 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Freitag 14 Februar 2025 (3 Tage vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 14 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 14 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 14 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 14 Februar 2025 (4 Tage vor) • Edgar (US Regulatory)

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Mittwoch 12 Februar 2025 (5 Tage vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 1 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
Montag 27 Januar 2025 (3 Wochen vor) • Business Wire

Form 8-K - Current report
Montag 13 Januar 2025 (1 Monat vor) • Edgar (US Regulatory)

Weitere Sarepta Therapeutics Inc New News-Artikel

Health Care Select Sector

Gold vs US Dollar

JP Morgan Chase

BNP Paribas (QX)

Deutsche Lufthansa

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen